Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0121 | 0.0793 | 0.8342 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0641 | 0.6855 | 0.9816 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0135 | 0.0951 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0278 | 0.2625 | 0.3759 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0121 | 0.0793 | 0.8342 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0641 | 0.6855 | 0.9816 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-1-like protein | 0.0278 | 0.2625 | 0.3759 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0653 | 0.6984 | 0.6984 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0121 | 0.0793 | 0.8342 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0385 | 0.3868 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0653 | 0.6984 | 1 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0121 | 0.0793 | 0.8342 |
Mycobacterium ulcerans | hypothetical protein | 0.0385 | 0.3868 | 0.5 |
Echinococcus granulosus | 6 phosphofructo 2 kinase:fructose 2 | 0.0653 | 0.6984 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0121 | 0.0793 | 0.8342 |
Giardia lamblia | Hypothetical protein | 0.0385 | 0.3868 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0053 | 0 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0053 | 0 | 0.5 |
Plasmodium falciparum | glutathione reductase | 0.0053 | 0 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0278 | 0.2625 | 0.3759 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0653 | 0.6984 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0053 | 0 | 0.5 |
Brugia malayi | glutathione reductase | 0.0053 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0385 | 0.3868 | 0.5 |
Onchocerca volvulus | 0.0653 | 0.6984 | 0.5 | |
Mycobacterium tuberculosis | Probable reductase | 0.0121 | 0.0793 | 0.8342 |
Loa Loa (eye worm) | hypothetical protein | 0.0374 | 0.374 | 0.5355 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0653 | 0.6984 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0278 | 0.2625 | 0.3759 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0653 | 0.6984 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0641 | 0.6855 | 0.9816 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0135 | 0.0951 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0653 | 0.6984 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0135 | 0.0951 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0135 | 0.0951 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0053 | 0 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0385 | 0.3868 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0653 | 0.6984 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0641 | 0.6855 | 0.9816 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0641 | 0.6855 | 0.9816 |
Plasmodium vivax | glutathione reductase, putative | 0.0053 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
F (ADMET) | = 94.677 % | Oral bioavailability in human | ChEMBL. | 23708011 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.